Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCEFUW)

• Drug Name: RB 2 Drug Info
• Synonyms: CHEMBL223344; Cibacron Blue 3GA Agarose; Cibacron Blue 3GA Agarose, saline suspension; Cibacron Blue 3GA Agarose, Type 300, saline suspension; Cibacron Blue 3GA Agarose, Type 100, saline suspension; Cibacron Blue 3GA Agarose, saline suspension, Fast flow; Cibacron Blue 3GA Agarose, Type 1000, saline suspension; Cibacron Blue 3GA Agarose, Type 3000, saline suspension; Cibacron Blue 3GA Agarose, Type 3000-CL, saline suspension; Cibacron Blue 3GA Agarose, Type 3000-L, lyophilized powder

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9875920
  TTD Drug ID: DMCEFUW

Molecule-Related Drug Atlas

Drug(s) Targeting Ecto-5'-nucleotidase (CD73)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TJ004309	DMFB54Y	Ovarian cancer	2C73	Phase 2	[3]
GS-1423	DMS25DL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
Oleclumab	DMLVNWO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
AB680	DMGONUE	Pancreatic cancer	2C10	Phase 1	[6]
TJ4309	DMM3U2Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
CPI-006	DMJSFTX	Advanced cancer	2A00-2F9Z	Phase 1	[8]
LY3475070	DMZLIWX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
NZV930	DMWN2FP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
PMID28870136-Compound-57	DME3HLC	N. A.	N. A.	Patented	[11]
PMID28870136-Compound-46	DM4FD7C	N. A.	N. A.	Patented	[11]

Drug(s) Targeting P2Y purinoceptor 6 (P2RY6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GC021109	DMQBEYV	Alzheimer disease	8A20	Phase 1	[12]
INS 316	DMTHMEI	Lung cancer	2C25.0	Discontinued in Phase 3	[13]
adenosine diphosphate	DMFUHKP	N. A.	N. A.	Investigative	[13]
2MeSATP	DMUE0W6	Discovery agent	N.A.	Investigative	[13]
PSB-0952	DMW19LB	Discovery agent	N.A.	Investigative	[2]
5BrUTP	DMEVRH4	Discovery agent	N.A.	Investigative	[13]
MRS2782	DMZSO4R	Discovery agent	N.A.	Investigative	[14]
MRS2578	DMKMPS6	Discovery agent	N.A.	Investigative	[15]
UDP-beta-S	DMMWHAV	Discovery agent	N.A.	Investigative	[16]
Up3U	DMKQWSB	Discovery agent	N.A.	Investigative	[16]

Drug(s) Targeting P2Y purinoceptor 2 (P2RY2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Diquafosol	DM64QG9	Dry eye disease	9E1Z	Phase 3	[17]
INS-37217	DMF93RQ	Cystic fibrosis	CA25	Phase 2	[17]
INS 316	DMTHMEI	Lung cancer	2C25.0	Discontinued in Phase 3	[18]
PSB-0963	DMBDVJ1	Discovery agent	N.A.	Investigative	[2]
UTPgammaS	DMKLB4O	Discovery agent	N.A.	Investigative	[19]
Acid blue 25	DMCU6XV	Discovery agent	N.A.	Investigative	[2]
5BrUTP	DMEVRH4	Discovery agent	N.A.	Investigative	[19]
2-thioUTP	DMJZ5V0	Discovery agent	N.A.	Investigative	[20]
SB-416	DMJW72O	Discovery agent	N.A.	Investigative	[1]
MDT-006	DMSF4UI	Constipation	DD91.1	Investigative	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ecto-5'-nucleotidase (CD73)	TTK0O6Y	5NTD_HUMAN	Inhibitor	[2]
P2Y purinoceptor 2 (P2RY2)	TTOZHQC	P2RY2_HUMAN	Inhibitor	[1]
P2Y purinoceptor 6 (P2RY6)	TTNVSKA	P2RY6_HUMAN	Inhibitor	[2]

References

• [1] Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 1;18(1):223-7.
• [2] Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
• [3] ClinicalTrials.gov (NCT05001347) A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ?) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors. U.S.National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of Agenus.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Discovery of AB680: A Potent and Selective Inhibitor of CD73. J Med Chem. 2020 Oct 22;63(20):11448-11468.
• [7] ClinicalTrials.gov (NCT04322006) A Phase I/II Study of TJ004309 for Advanced Solid Tumor. U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of Corvus Pharmaceuticals.
• [9] CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol. 2020 Apr 15;11:508.
• [10] Clinical pipeline report, company report or official report of Surface oncology.
• [11] Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8.
• [14] Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem. 2008 Jun 15;16(12):6319-32.
• [15] Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol. 2004 May 1;67(9):1763-70.
• [16] P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312.
• [17] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [18] Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol. 2001 Aug;32(2):122-8.
• [19] Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol. 1995 Sep;116(1):1619-27.
• [20] Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2006 Nov 30;49(24):7076-87.
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 324).